Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

被引：0
作者：
Thomas Köhnke
Christina Krupka
Johanna Tischer
Thomas Knösel
Marion Subklewe
机构：
[1] Ludwig-Maximilians-Universität (LMU),Department of Internal Medicine III
[2] Clinical Cooperation Group Immunotherapy at the Helmholtz Zentrum München,Institute of Pathology
[3] Ludwig-Maximilians-Universität (LMU),undefined
来源：
Journal of Hematology & Oncology | / 8卷
关键词：
ALL; Immunotherapy; Blinatumomab; Immune checkpoints; T cells; Combination therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The bispecific T cell engager blinatumomab has shown encouraging clinical activity in B-precursor acute lymphoblastic leukemia (ALL). However, about half of relapsed/refractory patients do not respond to therapy. Here, we present the case of a 32-year-old male patient with refractory B-precursor ALL who was resistant to treatment with blinatumomab. Bone marrow immunohistochemistry revealed T cell infiltrates and an increase in programmed death-ligand 1 (PD-L1)-positive ALL cells as a potential immune escape mechanism. We were able to recapitulate the clinical observation in vitro by showing that blinatumomab was not able to mediate cytotoxicity of CD19-positive ALL cells using autologous T cells. In contrast, the addition of healthy donor T cells led to lysis of ALL cells.
引用
收藏
相关论文
共 81 条
  • [1] Suresh T(2014)New antibody approaches to lymphoma therapy J Hematol Oncol 7 58-66
  • [2] Lee LX(2015)Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia J Hematol Oncol 8 104-66
  • [3] Joshi J(2015)Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies Mol Immunol 67 58-11
  • [4] Barta SK(2014)Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study Lancet Oncol 16 57-5
  • [5] Wu J(2013)Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia Clin Pharmacol 5 5-304
  • [6] Fu J(2012)Toward victory in adult ALL: blinatumomab joins in Blood 120 5094-33
  • [7] Zhang M(2015)Immune checkpoint inhibition in lymphoid disease Br J Haematol 170 291-7
  • [8] Liu D(2013)The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies J Hematol Oncol 6 74-25
  • [9] Zugmaier G(2015)Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway Trends Mol Med 21 24-65
  • [10] Klinger M(2015)Anti-programmed cell death protein-1/ligand-1 therapy in different cancers Br J Cancer 112 1421-65
123456789